Drug lookup | Fillwise

Apo-Olanzapine · DIN 02281791 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Olanzapine · DIN 02281791 Manufacturer: Apotex Inc.; listing date 2010-01-05 Health Canada: Marketed since 2009-10-09 · brand APO-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76745 · Verify on the e-Formulary ↗ (DIN 02281791)

Source record

DIN 02281791: Apo-Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02281791 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76745

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: resolved shortage (ended 2026-05-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02281791

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Olanzapine FC · DIN 02417243 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Olanzapine FC · DIN 02417243 Manufacturer: Jamp Pharma Corporation; listing date 2015-10-29 Health Canada: Marketed since 2015-06-05 · brand JAMP OLANZAPINE FC · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Olanzapine FC: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90188 · Verify on the e-Formulary ↗ (DIN 02417243)

Source record

DIN 02417243: Jamp Olanzapine FC Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417243 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90188

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: resolved shortage (ended 2023-09-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417243

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Olanzapine · DIN 02410141 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Olanzapine · DIN 02410141 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-09-18 · brand MINT-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89481 · Verify on the e-Formulary ↗ (DIN 02410141)

Source record

DIN 02410141: Mint-Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id MIN Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410141 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89481

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: resolved shortage (ended 2020-10-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410141

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olanzapine · DIN 02545586 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olanzapine · DIN 02545586 Manufacturer: Nora Pharma; listing date 2024-08-30 Health Canada: Marketed since 2024-04-08 · brand NRA-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103433 · Verify on the e-Formulary ↗ (DIN 02545586)

Source record

DIN 02545586: NRA-Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id NRA Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545586 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103433

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545586

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olanzapine · DIN 02372819 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olanzapine · DIN 02372819 Manufacturer: Sanis Health Inc.; listing date 2016-04-01 Health Canada: Marketed since 2015-10-28 · brand OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85790 · Verify on the e-Formulary ↗ (DIN 02372819)

Source record

DIN 02372819: Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372819 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85790

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372819

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olanzapine · DIN 02385864 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olanzapine · DIN 02385864 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-12 · brand OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87147 · Verify on the e-Formulary ↗ (DIN 02385864)

Source record

DIN 02385864: Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id SIV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385864 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87147

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385864

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Olanzapine · DIN 02303116 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Olanzapine · DIN 02303116 Manufacturer: Pharmascience Inc.; listing date 2009-11-19 Health Canada: Marketed since 2008-04-02 · brand PMS-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78844 · Verify on the e-Formulary ↗ (DIN 02303116)

Source record

DIN 02303116: PMS-Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id PMS Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02303116 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78844

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: resolved shortage (ended 2019-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02303116

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Olanzapine · DIN 02310341 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Olanzapine · DIN 02310341 Manufacturer: Sandoz Canada Inc.; listing date 2010-10-28 Health Canada: Marketed since 2009-12-06 · brand SANDOZ OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79599 · Verify on the e-Formulary ↗ (DIN 02310341)

Source record

DIN 02310341: Sandoz Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02310341 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79599

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: anticipated shortage (last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02310341

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Olanzapine · DIN 02276712 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Olanzapine · DIN 02276712 Manufacturer: Teva Canada Limited; listing date 2007-07-12 Health Canada: Marketed since 2010-04-30 · brand TEVA-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Olanzapine: Formulary list price $0.1772/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76239 · Verify on the e-Formulary ↗ (DIN 02276712)

Source record

DIN 02276712: Teva-Olanzapine Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id TEV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.1772; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02276712 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76239

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Zyprexa · DIN 02229250 · $0.1772

Shortage status: resolved shortage (ended 2025-11-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02276712

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zyprexa · DIN 02229250 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Zyprexa · DIN 02229250 Manufacturer: Eli Lilly Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 2026-02-25 · brand ZYPREXA · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 2.5 MG · company Cheplapharm registration gmbh · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.1772 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43530 · Verify on the e-Formulary ↗ (DIN 02229250)

Source record

DIN 02229250: Zyprexa Raw flags: sec3=Y Item: 281608195; group id 498; item number 1285; lccId None; manufacturer id LIL Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $2.3456; ministry $0.1772 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229250 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43530

Interchangeable products

AG-Olanzapine FC · DIN 02487608 · $0.1772 Apo-Olanzapine · DIN 02281791 · $0.1772 Co Olanzapine · DIN 02325659 · $0.1772 Jamp Olanzapine FC · DIN 02417243 · $0.1772 Mint-Olanzapine · DIN 02410141 · $0.1772 NRA-Olanzapine · DIN 02545586 · $0.1772 Olanzapine · DIN 02372819 · $0.1772 Olanzapine · DIN 02385864 · $0.1772 PMS-Olanzapine · DIN 02303116 · $0.1772 Sandoz Olanzapine · DIN 02310341 · $0.1772 Teva-Olanzapine · DIN 02276712 · $0.1772

Shortage status: resolved shortage (ended 2026-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229250

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Olanzapine ODT · DIN 02360616 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Olanzapine ODT · DIN 02360616 Manufacturer: Apotex Inc.; listing date 2011-06-08 Health Canada: Marketed since 2011-11-16 · brand APO-OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84558 · Verify on the e-Formulary ↗ (DIN 02360616)

Source record

DIN 02360616: Apo-Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id APX Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02360616 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84558

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: resolved shortage (ended 2026-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02360616

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Olanzapine ODT · DIN 02448726 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Olanzapine ODT · DIN 02448726 Manufacturer: Auro Pharma Inc.; listing date 2016-05-31 Health Canada: Marketed since 2015-12-01 · brand AURO-OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93444 · Verify on the e-Formulary ↗ (DIN 02448726)

Source record

DIN 02448726: Auro-Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id AUR Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02448726 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93444

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: discontinued (2023-11-21, reported by AURO PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02448726

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Olanzapine ODT · DIN 02406624 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Olanzapine ODT · DIN 02406624 Manufacturer: Jamp Pharma Corporation; listing date 2013-08-29 Health Canada: Marketed since 2026-03-10 · brand JAMP OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89131 · Verify on the e-Formulary ↗ (DIN 02406624)

Source record

DIN 02406624: Jamp-Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id JPC Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02406624 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89131

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: resolved shortage (ended 2026-03-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02406624

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Olanzapine ODT · DIN 02436965 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Olanzapine ODT · DIN 02436965 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-07-29 Health Canada: Marketed since 2015-03-18 · brand MINT-OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92128 · Verify on the e-Formulary ↗ (DIN 02436965)

Source record

DIN 02436965: Mint-Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id MIN Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436965 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92128

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: resolved shortage (ended 2021-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02436965

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olanzapine ODT · DIN 02536188 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olanzapine ODT · DIN 02536188 Manufacturer: Nora Pharma; listing date 2024-08-30 Health Canada: Marketed since 2024-04-08 · brand NRA-OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102498 · Verify on the e-Formulary ↗ (DIN 02536188)

Source record

DIN 02536188: NRA-Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id NRA Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536188 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102498

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536188

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olanzapine ODT · DIN 02343665 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olanzapine ODT · DIN 02343665 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18 Health Canada: Marketed since 2018-06-08 · brand OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82910 · Verify on the e-Formulary ↗ (DIN 02343665)

Source record

DIN 02343665: Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id SIV Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02343665 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82910

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: resolved shortage (ended 2024-01-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02343665

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olanzapine ODT · DIN 02352974 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olanzapine ODT · DIN 02352974 Manufacturer: Sanis Health Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-03-25 · brand OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83820 · Verify on the e-Formulary ↗ (DIN 02352974)

Source record

DIN 02352974: Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id SAI Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352974 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83820

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: anticipated shortage (last updated 2026-05-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352974

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Olanzapine ODT · DIN 02303191 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Olanzapine ODT · DIN 02303191 Manufacturer: Pharmascience Inc.; listing date 2010-01-05 Health Canada: Marketed since 2009-10-15 · brand PMS-OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78852 · Verify on the e-Formulary ↗ (DIN 02303191)

Source record

DIN 02303191: PMS-Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id PMS Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02303191 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78852

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02303191

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Olanzapine ODT · DIN 02327775 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Olanzapine ODT · DIN 02327775 Manufacturer: Sandoz Canada Inc.; listing date 2010-01-05 Health Canada: Marketed since 2010-02-26 · brand SANDOZ OLANZAPINE ODT · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Olanzapine ODT: Formulary list price $0.3574/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81318 · Verify on the e-Formulary ↗ (DIN 02327775)

Source record

DIN 02327775: Sandoz Olanzapine ODT Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id SDZ Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3574; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327775 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81318

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Zyprexa Zydis · DIN 02243086 · $0.3574

Shortage status: active shortage (reported 2026-08-10, estimated to end 2026-11-06, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327775

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zyprexa Zydis · DIN 02243086 · 5mg · Rapid Dissolve tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Zyprexa Zydis · DIN 02243086 Manufacturer: Eli Lilly Canada Inc.; listing date 2001-10-11 Health Canada: Marketed since 2026-03-24 · brand ZYPREXA ZYDIS · ATC N05AH03 OLANZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients OLANZAPINE 5 MG · company Cheplapharm registration gmbh · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3574 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66953 · Verify on the e-Formulary ↗ (DIN 02243086)

Source record

DIN 02243086: Zyprexa Zydis Raw flags: sec3=Y Item: 281608206; group id 498; item number 1281; lccId None; manufacturer id LIL Source form: Rapid Dissolve Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $4.5882; ministry $0.3574 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243086 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66953

Interchangeable products

Act Olanzapine ODT · DIN 02327562 · $0.3574 Apo-Olanzapine ODT · DIN 02360616 · $0.3574 Auro-Olanzapine ODT · DIN 02448726 · $0.3574 Jamp-Olanzapine ODT · DIN 02406624 · $0.3574 Mint-Olanzapine ODT · DIN 02436965 · $0.3574 NRA-Olanzapine ODT · DIN 02536188 · $0.3574 Olanzapine ODT · DIN 02343665 · $0.3574 Olanzapine ODT · DIN 02352974 · $0.3574 PMS-Olanzapine ODT · DIN 02303191 · $0.3574 Ran-Olanzapine ODT · DIN 02414090 · $0.3574 Sandoz Olanzapine ODT · DIN 02327775 · $0.3574

Shortage status: resolved shortage (ended 2026-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243086

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Olanzapine · DIN 02281805 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Olanzapine · DIN 02281805 Manufacturer: Apotex Inc.; listing date 2010-01-05 Health Canada: Marketed since 2009-10-09 · brand APO-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Olanzapine: Formulary list price $0.3544/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3544 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76746 · Verify on the e-Formulary ↗ (DIN 02281805)

Source record

DIN 02281805: Apo-Olanzapine Raw flags: sec3=Y Item: 281608187; group id 498; item number 1286; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3544; ministry $0.3544 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02281805 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76746

Interchangeable products

AG-Olanzapine FC · DIN 02487616 · $0.3544 Co Olanzapine · DIN 02325667 · $0.3544 Jamp Olanzapine FC · DIN 02417251 · $0.3544 Mint-Olanzapine · DIN 02410168 · $0.3544 NRA-Olanzapine · DIN 02545594 · $0.3544 Olanzapine · DIN 02372827 · $0.3544 Olanzapine · DIN 02385872 · $0.3544 PMS-Olanzapine · DIN 02303159 · $0.3544 Ran-Olanzapine · DIN 02403072 · $0.3544 Sandoz Olanzapine · DIN 02310368 · $0.3544 Teva-Olanzapine · DIN 02276720 · $0.3544 Zyprexa · DIN 02229269 · $0.3544

Shortage status: resolved shortage (ended 2020-05-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02281805

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Olanzapine FC · DIN 02417251 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Olanzapine FC · DIN 02417251 Manufacturer: Jamp Pharma Corporation; listing date 2015-10-29 Health Canada: Marketed since 2015-06-05 · brand JAMP OLANZAPINE FC · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Olanzapine FC: Formulary list price $0.3544/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3544 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90189 · Verify on the e-Formulary ↗ (DIN 02417251)

Source record

DIN 02417251: Jamp Olanzapine FC Raw flags: sec3=Y Item: 281608187; group id 498; item number 1286; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3544; ministry $0.3544 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417251 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90189

Interchangeable products

AG-Olanzapine FC · DIN 02487616 · $0.3544 Apo-Olanzapine · DIN 02281805 · $0.3544 Co Olanzapine · DIN 02325667 · $0.3544 Mint-Olanzapine · DIN 02410168 · $0.3544 NRA-Olanzapine · DIN 02545594 · $0.3544 Olanzapine · DIN 02372827 · $0.3544 Olanzapine · DIN 02385872 · $0.3544 PMS-Olanzapine · DIN 02303159 · $0.3544 Ran-Olanzapine · DIN 02403072 · $0.3544 Sandoz Olanzapine · DIN 02310368 · $0.3544 Teva-Olanzapine · DIN 02276720 · $0.3544 Zyprexa · DIN 02229269 · $0.3544

Shortage status: resolved shortage (ended 2026-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417251

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Olanzapine · DIN 02410168 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Olanzapine · DIN 02410168 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-09-18 · brand MINT-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 5 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Olanzapine: Formulary list price $0.3544/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3544 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89482 · Verify on the e-Formulary ↗ (DIN 02410168)

Source record

DIN 02410168: Mint-Olanzapine Raw flags: sec3=Y Item: 281608187; group id 498; item number 1286; lccId None; manufacturer id MIN Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3544; ministry $0.3544 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410168 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89482

Interchangeable products

AG-Olanzapine FC · DIN 02487616 · $0.3544 Apo-Olanzapine · DIN 02281805 · $0.3544 Co Olanzapine · DIN 02325667 · $0.3544 Jamp Olanzapine FC · DIN 02417251 · $0.3544 NRA-Olanzapine · DIN 02545594 · $0.3544 Olanzapine · DIN 02372827 · $0.3544 Olanzapine · DIN 02385872 · $0.3544 PMS-Olanzapine · DIN 02303159 · $0.3544 Ran-Olanzapine · DIN 02403072 · $0.3544 Sandoz Olanzapine · DIN 02310368 · $0.3544 Teva-Olanzapine · DIN 02276720 · $0.3544 Zyprexa · DIN 02229269 · $0.3544

Shortage status: resolved shortage (ended 2020-10-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410168

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olanzapine · DIN 02545594 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olanzapine · DIN 02545594 Manufacturer: Nora Pharma; listing date 2024-08-30 Health Canada: Marketed since 2024-04-08 · brand NRA-OLANZAPINE · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 5 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olanzapine: Formulary list price $0.3544/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3544 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103434 · Verify on the e-Formulary ↗ (DIN 02545594)

Source record

DIN 02545594: NRA-Olanzapine Raw flags: sec3=Y Item: 281608187; group id 498; item number 1286; lccId None; manufacturer id NRA Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3544; ministry $0.3544 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545594 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103434

Interchangeable products

AG-Olanzapine FC · DIN 02487616 · $0.3544 Apo-Olanzapine · DIN 02281805 · $0.3544 Co Olanzapine · DIN 02325667 · $0.3544 Jamp Olanzapine FC · DIN 02417251 · $0.3544 Mint-Olanzapine · DIN 02410168 · $0.3544 Olanzapine · DIN 02372827 · $0.3544 Olanzapine · DIN 02385872 · $0.3544 PMS-Olanzapine · DIN 02303159 · $0.3544 Ran-Olanzapine · DIN 02403072 · $0.3544 Sandoz Olanzapine · DIN 02310368 · $0.3544 Teva-Olanzapine · DIN 02276720 · $0.3544 Zyprexa · DIN 02229269 · $0.3544

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545594

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Look up one drug

OLANZAPINE

Apo-Olanzapine · DIN 02281791 · 2.5mg · tablet

Jamp Olanzapine FC · DIN 02417243 · 2.5mg · tablet

Mint-Olanzapine · DIN 02410141 · 2.5mg · tablet

NRA-Olanzapine · DIN 02545586 · 2.5mg · tablet

Olanzapine · DIN 02372819 · 2.5mg · tablet

Olanzapine · DIN 02385864 · 2.5mg · tablet

PMS-Olanzapine · DIN 02303116 · 2.5mg · tablet

Sandoz Olanzapine · DIN 02310341 · 2.5mg · tablet

Teva-Olanzapine · DIN 02276712 · 2.5mg · tablet

Zyprexa · DIN 02229250 · 2.5mg · tablet

Apo-Olanzapine ODT · DIN 02360616 · 5mg · Rapid Dissolve tablet

Auro-Olanzapine ODT · DIN 02448726 · 5mg · Rapid Dissolve tablet

Jamp-Olanzapine ODT · DIN 02406624 · 5mg · Rapid Dissolve tablet

Mint-Olanzapine ODT · DIN 02436965 · 5mg · Rapid Dissolve tablet

NRA-Olanzapine ODT · DIN 02536188 · 5mg · Rapid Dissolve tablet

Olanzapine ODT · DIN 02343665 · 5mg · Rapid Dissolve tablet

Olanzapine ODT · DIN 02352974 · 5mg · Rapid Dissolve tablet

PMS-Olanzapine ODT · DIN 02303191 · 5mg · Rapid Dissolve tablet

Sandoz Olanzapine ODT · DIN 02327775 · 5mg · Rapid Dissolve tablet

Zyprexa Zydis · DIN 02243086 · 5mg · Rapid Dissolve tablet

Apo-Olanzapine · DIN 02281805 · 5mg · tablet

Jamp Olanzapine FC · DIN 02417251 · 5mg · tablet

Mint-Olanzapine · DIN 02410168 · 5mg · tablet

NRA-Olanzapine · DIN 02545594 · 5mg · tablet

Matched class: 28:16:08 Tranquilizers

ASENAPINE

LOXAPINE SUCCINATE

QUETIAPINE

CLOZAPINE

ARIPIPRAZOLE

BREXPIPRAZOLE

CARIPRAZINE

CHLORPROMAZINE

FLUPENTIXOL DECANOATE

FLUPENTIXOL DIHYDROCHLORIDE

FLUPHENAZINE HCL

HALOPERIDOL

Availability